Claus Normann
Overview
Explore the profile of Claus Normann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
1411
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Vestring S, Wolf E, Dinkelacker J, Frase S, Hessling-Zeinen C, Insan S, et al.
J Neuroeng Rehabil
. 2024 Sep;
21(1):162.
PMID: 39289746
Background: Transcranial direct current stimulation (tDCS) is capable of eliciting changes in cortical neuroplasticity. Increasing duration or repetition of tDCS during the after-effects of a first stimulation has been hypothesized...
3.
Sarrazin D, Gardner W, Marchese C, Balzinger M, Ramanathan C, Schott M, et al.
Nat Commun
. 2024 Aug;
15(1):7257.
PMID: 39179578
Depression is associated with dysregulated circadian rhythms, but the role of intrinsic clocks in mood-controlling brain regions remains poorly understood. We found increased circadian negative loop and decreased positive clock...
4.
Sun L, Apweiler M, Tirkey A, Klett D, Normann C, Dietz G, et al.
Int J Mol Sci
. 2024 Aug;
25(15).
PMID: 39125680
Inflammatory processes in the brain can exert important neuroprotective functions. However, in neurological and psychiatric disorders, it is often detrimental due to chronic microglial over-activation and the dysregulation of cytokines...
5.
Sun L, Apweiler M, Normann C, Grathwol C, Hurrle T, Grassle S, et al.
Pharmaceuticals (Basel)
. 2024 Jun;
17(6).
PMID: 38931342
Chronic inflammation is driven by proinflammatory cytokines such as interleukin 6 (IL-6), tumor necrosis factor-α (TNF-α), and chemokines, such as c-c motif chemokine ligand 2 (CCL2), CCL3, C-X-C motif chemokine...
6.
Apweiler M, Saliba S, Sun L, Streyczek J, Normann C, Hellwig S, et al.
Mol Psychiatry
. 2024 May;
29(12):3779-3788.
PMID: 38796643
Pharmacological treatment of psychiatric disorders remains challenging in clinical, pharmacological, and scientific practice. Even if many different substances are established for treating different psychiatric conditions, subgroups of patients show only...
7.
Sun L, Saliba S, Apweiler M, Akmermer K, Herlan C, Grathwol C, et al.
Int J Mol Sci
. 2024 Apr;
25(8).
PMID: 38674048
Inflammation processes of the central nervous system (CNS) play a vital role in the pathogenesis of several neurological and psychiatric disorders like depression. These processes are characterized by the activation...
8.
Soldini A, Vogelmann U, Aust S, Goerigk S, Plewnia C, Fallgatter A, et al.
Eur Arch Psychiatry Clin Neurosci
. 2024 Feb;
PMID: 38407625
Transcranial direct current stimulation (tDCS) of the prefrontal cortex might beneficially influence neurocognitive dysfunctions associated with major depressive disorder (MDD). However, previous studies of neurocognitive effects of tDCS have been...
9.
Vestring S, Galuba V, Kern E, Voita S, Berens F, Nasiri D, et al.
J Affect Disord
. 2024 Jan;
350:895-899.
PMID: 38266928
Background: Ketamine has emerged as an effective treatment option for patients with treatment-resistant depression. However, there is limited evidence of the benefits of ketamine in inpatients with multiple treatment resistance...
10.
Vestring S, Dorner A, Scholliers J, Ehrenberger K, Kiss A, Arenz L, et al.
Transl Psychiatry
. 2024 Jan;
14(1):18.
PMID: 38195548
The partial N-methyl-D-aspartate receptor (NMDAR) agonist D-Cycloserine (DCS) has been evaluated for the treatment of a wide variety of psychiatric disorders, including dementia, schizophrenia, depression and for the augmentation of...